Experience
Finnegan represented Eli Lilly on first genetically engineered biologic in the United States
Regents of the Univ. of Cal.
Eli Lilly and Company
Finnegan successfully represented Eli Lilly in a litigation against Genentech and the Regents of the University of California (UC) regarding Eli Lilly’s Humulin® insulin product, the first biotechnology product to be marketed in the United States. We obtained judgment, affirmed on appeal, that UC’s patents were either not infringed or invalid under the written description requirement of 35 U.S.C. § 112.
Regents of the Univ. of Cal. v. Eli Lilly and Company, 92-cv-00224, S.D. Ind., Judges Dillin, Godich
Eli Lilly and Company v. Regents of the Univ. of Cal., 96-1175, Fed. Cir., Judges Newman, Lourie, Bryson